Abstract | BACKGROUND: PATIENTS AND METHODS: Metastatic renal cell carcinoma patients with measurable disease entered the study. FUDR was administered as a constant-rate continuous infusion for 14 days every 28 days at a starting daily dose of 0.1 mg/kg and with dose escalations of 0.025 mg/kg/day at each subsequent cycle if WHO > or = 2 toxicity had not occurred. IFN-alpha 2b 10 x 10(6) I.U. was administered intramuscularly 3 times per week. RESULTS: Forty-two patients entered the study and a total of 272 cycles of FUDR + alpha 2b-IFN were administered. In 41 evaluable patients WHO grade III-IV toxic effects included nausea and vomiting (22%), diarrhea (32%), stomatitis (12%), fatigue (27%) and anorexia (12%). It was possible to increase the initial FUDR does in 21 (50%) patients; the median FUDR dose intensity was 0.35 mg/kg/week (range 0.18-0.54). Among 39 evaluable patients, 3 (7.5%) complete and 10 (25.5%) partial responses were observed (response rate 33%, 95% confidence interval (CI) 19%-50%) which lasted a median of 13 months (5.5-40+). Responses also occurred in liver (2), in patients pretreated with systemic therapy (5) and in patients who had other unfavourable prognostic characteristics (7). Median progression-free and survival times were 9 and 16 months, respectively. CONCLUSIONS: In this study FUDR + alpha 2b-IFN demonstrated interesting activity in metastatic renal cell carcinoma, showing promise also in patients with unfavourable prognostic characteristics. The antitumor activity of FUDR and alpha 2b-IFN seems to be cumulative, but cumulative toxicity is also observed. These results require confirmation in randomised trials.
|
Authors | A Falcone, C Cianci, E Pfanner, S Ricci, M Lencioni, I Brunetti, P C Giulianotti, L Vannucci, F Mosca, P F Conte |
Journal | Annals of oncology : official journal of the European Society for Medical Oncology
(Ann Oncol)
Vol. 7
Issue 6
Pg. 601-5
(Aug 1996)
ISSN: 0923-7534 [Print] England |
PMID | 8879374
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article)
|
Chemical References |
- Interferon alpha-2
- Interferon-alpha
- Recombinant Proteins
- Floxuridine
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Carcinoma, Renal Cell
(drug therapy)
- Drug Administration Schedule
- Drug Synergism
- Female
- Floxuridine
(administration & dosage)
- Humans
- Infusions, Intravenous
- Injections, Intramuscular
- Interferon alpha-2
- Interferon-alpha
(administration & dosage)
- Kidney Neoplasms
(drug therapy)
- Male
- Middle Aged
- Neoplasm Metastasis
- Recombinant Proteins
|